November 26, 2013
. Agreement established after positive pre-clinical results were obtained by DBV and University of Geneva combining DBV’s and BioNet’s unique technologies . A Phase I, clinical proof of concept study will be initiated in H2 2014 by the University of Geneva DBV Technologies (Euronext Paris: DBV), creator of Viaskin®, announced today that it has entered...


Seven research institutions receive DKK 20 million for coronavirus research
1. April 2020
How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge